Proteome Sciences PLC (PRM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Proteome Sciences PLC (PRM) has a cash flow conversion efficiency ratio of 0.104x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-897.00K ≈ $-109.14 USD) by net assets (GBX-8.58 Million ≈ $-1.04K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Proteome Sciences PLC - Cash Flow Conversion Efficiency Trend (1994–2024)
This chart illustrates how Proteome Sciences PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Proteome Sciences PLC (PRM) total liabilities for a breakdown of total debt and financial obligations.
Proteome Sciences PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Proteome Sciences PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Heavitree Brewery A
LSE:HVTA
|
0.010x |
|
Sutton Harbour Holdings plc
LSE:SUH
|
-0.042x |
|
Winners
KQ:479960
|
-0.004x |
|
TC Unterhaltungselektronik AG
F:TCU
|
N/A |
|
Gem Diamonds Ltd
LSE:GEMD
|
-0.037x |
|
Argo Blockchain PLC
LSE:ARB
|
0.135x |
|
Walker Crips Group PLC
LSE:WCW
|
-0.456x |
|
Seed Innovations Ltd
LSE:SEED
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Proteome Sciences PLC (1994–2024)
The table below shows the annual cash flow conversion efficiency of Proteome Sciences PLC from 1994 to 2024. For the full company profile with market capitalisation and key ratios, see Proteome Sciences PLC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-6.52 Million ≈ $-792.81 |
GBX-826.00K ≈ $-100.50 |
0.127x | -19.20% |
| 2023-12-31 | GBX-3.07 Million ≈ $-373.04 |
GBX-481.00K ≈ $-58.52 |
0.157x | +507640.31% |
| 2022-12-31 | GBX69.26 Billion ≈ $8.43 Million |
GBX2.14 Million ≈ $260.38 |
0.000x | +172.90% |
| 2021-12-31 | GBX70.04 Billion ≈ $8.52 Million |
GBX793.00K ≈ $96.49 |
0.000x | -52.16% |
| 2020-12-31 | GBX66.88 Billion ≈ $8.14 Million |
GBX1.58 Million ≈ $192.61 |
0.000x | +100.01% |
| 2019-12-31 | GBX65.66 Billion ≈ $7.99 Million |
GBX-21.45 Billion ≈ $-2.61 Million |
-0.327x | -40.98% |
| 2018-12-31 | GBX63.78 Billion ≈ $7.76 Million |
GBX-14.78 Billion ≈ $-1.80 Million |
-0.232x | -127.58% |
| 2017-12-31 | GBX66.02 Billion ≈ $8.03 Million |
GBX55.47 Billion ≈ $6.75 Million |
0.840x | +3000.54% |
| 2016-12-31 | GBX1.09 Trillion ≈ $133.11 Million |
GBX-31.70 Billion ≈ $-3.86 Million |
-0.029x | -104.09% |
| 2015-12-31 | GBX65.86 Billion ≈ $8.01 Million |
GBX46.63 Billion ≈ $5.67 Million |
0.708x | +845.17% |
| 2014-12-31 | GBX65.96 Billion ≈ $8.03 Million |
GBX-6.27 Billion ≈ $-762.51K |
-0.095x | +47.39% |
| 2013-12-31 | GBX63.95 Billion ≈ $7.78 Million |
GBX-11.55 Billion ≈ $-1.41 Million |
-0.181x | -104.13% |
| 2012-12-31 | GBX-766.53K ≈ $-93.26 |
GBX-3.35 Million ≈ $-408.01 |
4.375x | +379.37% |
| 2011-12-31 | GBX3.30 Million ≈ $401.39 |
GBX-5.17 Million ≈ $-628.55 |
-1.566x | -382.40% |
| 2010-12-31 | GBX7.22 Million ≈ $878.34 |
GBX4.00 Million ≈ $487.05 |
0.555x | +72.36% |
| 2009-12-31 | GBX-9.24 Million ≈ $-1.12K |
GBX-2.97 Million ≈ $-361.61 |
0.322x | -56.11% |
| 2008-12-31 | GBX-5.62 Million ≈ $-684.28 |
GBX-4.12 Million ≈ $-501.53 |
0.733x | -61.23% |
| 2007-12-31 | GBX-2.17 Million ≈ $-263.42 |
GBX-4.09 Million ≈ $-498.00 |
1.891x | +235.68% |
| 2006-12-31 | GBX2.59 Million ≈ $314.88 |
GBX-3.61 Million ≈ $-438.75 |
-1.393x | -129.38% |
| 2005-12-31 | GBX7.85 Million ≈ $955.24 |
GBX-4.77 Million ≈ $-580.25 |
-0.607x | -41.83% |
| 2004-12-31 | GBX8.80 Million ≈ $1.07K |
GBX-3.77 Million ≈ $-458.72 |
-0.428x | -4.05% |
| 2003-12-31 | GBX11.84 Million ≈ $1.44K |
GBX-4.88 Million ≈ $-593.15 |
-0.412x | -48.86% |
| 2002-12-31 | GBX11.84 Million ≈ $1.44K |
GBX-3.27 Million ≈ $-398.35 |
-0.276x | +55.36% |
| 2001-12-31 | GBX2.51 Million ≈ $305.27 |
GBX-1.55 Million ≈ $-189.08 |
-0.619x | -43.31% |
| 2000-12-31 | GBX2.64 Million ≈ $321.21 |
GBX-1.14 Million ≈ $-138.83 |
-0.432x | +96.38% |
| 1999-12-31 | GBX105.00K ≈ $12.78 |
GBX-1.25 Million ≈ $-152.58 |
-11.943x | -698.00% |
| 1998-12-31 | GBX1.03 Million ≈ $125.44 |
GBX-1.54 Million ≈ $-187.74 |
-1.497x | -233.77% |
| 1997-12-31 | GBX2.87 Million ≈ $348.95 |
GBX-1.29 Million ≈ $-156.47 |
-0.448x | +91.59% |
| 1996-12-31 | GBX321.00K ≈ $39.06 |
GBX-1.71 Million ≈ $-208.30 |
-5.333x | -278.00% |
| 1994-10-31 | GBX-270.00K ≈ $-32.85 |
GBX-809.00K ≈ $-98.43 |
2.996x | -- |
About Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more